Literature DB >> 30718231

Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition.

Olive S Eckstein1,2, Johannes Visser3, Carlos Rodriguez-Galindo4,5, Carl E Allen1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30718231      PMCID： PMC6460419          DOI： 10.1182/blood-2018-10-878363

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  26 in total

1.  Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.

Authors:  Sébastien Héritier; Mathilde Jehanne; Guy Leverger; Jean-François Emile; Jean-Claude Alvarez; Julien Haroche; Jean Donadieu
Journal:  JAMA Oncol       Date:  2015-09       Impact factor: 31.777

2.  High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.

Authors:  Noah A Brown; Larissa V Furtado; Bryan L Betz; Mark J Kiel; Helmut C Weigelin; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  Blood       Date:  2014-06-30       Impact factor: 22.113

3.  Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.

Authors:  Jean Donadieu; Frederic Bernard; Max van Noesel; Mohamed Barkaoui; Odile Bardet; Rosella Mura; Maurizio Arico; Christophe Piguet; Virginie Gandemer; Corinne Armari Alla; Niels Clausen; Eric Jeziorski; Anne Lambilliote; Sheila Weitzman; Jan Inge Henter; Cor Van Den Bos
Journal:  Blood       Date:  2015-07-20       Impact factor: 22.113

4.  Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.

Authors:  Helmut Gadner; Milen Minkov; Nicole Grois; Ulrike Pötschger; Elfriede Thiem; Maurizio Aricò; Itziar Astigarraga; Jorge Braier; Jean Donadieu; Jan-Inge Henter; Gritta Janka-Schaub; Kenneth L McClain; Sheila Weitzman; Kevin Windebank; Stephan Ladisch
Journal:  Blood       Date:  2013-04-15       Impact factor: 22.113

5.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Authors:  David M Hyman; Igor Puzanov; Vivek Subbiah; Jason E Faris; Ian Chau; Jean-Yves Blay; Jürgen Wolf; Noopur S Raje; Eli L Diamond; Antoine Hollebecque; Radj Gervais; Maria Elena Elez-Fernandez; Antoine Italiano; Ralf-Dieter Hofheinz; Manuel Hidalgo; Emily Chan; Martin Schuler; Susan Frances Lasserre; Martina Makrutzki; Florin Sirzen; Maria Luisa Veronese; Josep Tabernero; José Baselga
Journal:  N Engl J Med       Date:  2015-08-20       Impact factor: 91.245

6.  Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.

Authors:  David O Azorsa; David W Lee; Daniel H Wai; Ranjan Bista; Apurvi R Patel; Eiman Aleem; Michael M Henry; Robert J Arceci
Journal:  Pediatr Blood Cancer       Date:  2018-05-16       Impact factor: 3.167

7.  Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

Authors:  Eli L Diamond; Benjamin H Durham; Julien Haroche; Zhan Yao; Jing Ma; Sameer A Parikh; Zhaoming Wang; John Choi; Eunhee Kim; Fleur Cohen-Aubart; Stanley Chun-Wei Lee; Yijun Gao; Jean-Baptiste Micol; Patrick Campbell; Michael P Walsh; Brooke Sylvester; Igor Dolgalev; Olga Aminova; Adriana Heguy; Paul Zappile; Joy Nakitandwe; Chezi Ganzel; James D Dalton; David W Ellison; Juvianee Estrada-Veras; Mario Lacouture; William A Gahl; Philip J Stephens; Vincent A Miller; Jeffrey S Ross; Siraj M Ali; Samuel R Briggs; Omotayo Fasan; Jared Block; Sebastien Héritier; Jean Donadieu; David B Solit; David M Hyman; José Baselga; Filip Janku; Barry S Taylor; Christopher Y Park; Zahir Amoura; Ahmet Dogan; Jean-Francois Emile; Neal Rosen; Tanja A Gruber; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2015-11-13       Impact factor: 39.397

8.  Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

Authors:  Eli L Diamond; Vivek Subbiah; A Craig Lockhart; Jean-Yves Blay; Igor Puzanov; Ian Chau; Noopur S Raje; Jurgen Wolf; Joseph P Erinjeri; Jean Torrisi; Mario Lacouture; Elena Elez; Ferran Martínez-Valle; Benjamin Durham; Maria E Arcila; Gary Ulaner; Omar Abdel-Wahab; Bethany Pitcher; Martina Makrutzki; Todd Riehl; José Baselga; David M Hyman
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

9.  RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions.

Authors:  Brandon Hogstad; Marie-Luise Berres; Rikhia Chakraborty; Jun Tang; Camille Bigenwald; Madhavika Serasinghe; Karen Phaik Har Lim; Howard Lin; Tsz-Kwong Man; Romain Remark; Samantha Baxter; Veronika Kana; Stefan Jordan; Zoi Karoulia; Wing-Hong Kwan; Marylene Leboeuf; Elisa Brandt; Helene Salmon; Kenneth McClain; Poulikos Poulikakos; Jerry Chipuk; Willem J M Mulder; Carl E Allen; Miriam Merad
Journal:  J Exp Med       Date:  2017-12-20       Impact factor: 14.307

10.  A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease.

Authors:  Elvira Mass; Christian E Jacome-Galarza; Thomas Blank; Tomi Lazarov; Benjamin H Durham; Neval Ozkaya; Alessandro Pastore; Marius Schwabenland; Young Rock Chung; Marc K Rosenblum; Marco Prinz; Omar Abdel-Wahab; Frederic Geissmann
Journal:  Nature       Date:  2017-08-30       Impact factor: 49.962
View more
  17 in total

1.  BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor.

Authors:  Rosemarie Mastropolo; Allison Close; Steven W Allen; Kenneth L McClain; Scott Maurer; Jennifer Picarsic
Journal:  Blood Adv       Date:  2019-06-25

2.  Three decades of progress from surgery to medical therapy for isolated neuroaxis BRAF V600E-positive Langerhans cell histiocytosis management: illustrative case.

Authors:  Nallammai Muthiah; Kamil W Nowicki; Jennifer L Picarsic; Michael P D'Angelo; Daniel F Marker; Edward G Andrews; Edward A Monaco; Ajay Niranjan
Journal:  J Neurosurg Case Lessons       Date:  2021-05-10

Review 3.  Histiocytic disorders.

Authors:  Kenneth L McClain; Camille Bigenwald; Matthew Collin; Julien Haroche; Rebecca A Marsh; Miriam Merad; Jennifer Picarsic; Karina B Ribeiro; Carl E Allen
Journal:  Nat Rev Dis Primers       Date:  2021-10-07       Impact factor: 65.038

4.  Management of severe pulmonary Langerhans cell histiocytosis in children.

Authors:  Olive S Eckstein; Jed G Nuchtern; George B Mallory; R Paul Guillerman; Matthew A Musick; Mhairi Barclay; Jayesh M Bhatt; Patrick Davies; Richard G Grundy; Alice Martin; Tom Hilliard; Stephen P Lowis; Susan Picton; Vasanta Nanduri; Johannes Visser; Carl E Allen; Kenneth L McClain
Journal:  Pediatr Pulmonol       Date:  2020-06-08

5.  BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology.

Authors:  C Matthias Wilk; Rikhia Chakraborty; Steven T Chen; Carl E Allen; Miriam Merad; Camille Bigenwald; Jessica Le Berichel; Alexandra Tabachnikova; Rebecca Mancusi; Harshal Abhyankar; Maria Casanova-Acebes; Ilaria Laface; Guray Akturk; Jenielle Jobson; Zoi Karoulia; Jerome C Martin; John Grout; Anahita Rafiei; Howard Lin; Markus G Manz; Alessia Baccarini; Poulikos I Poulikakos; Brian D Brown; Sacha Gnjatic; Amaia Lujambio; Kenneth L McClain; Jennifer Picarsic
Journal:  Nat Med       Date:  2021-05-06       Impact factor: 87.241

6.  Dasatinib induces a dramatic response in a child with refractory juvenile xanthogranuloma with a novel MRC1-PDGFRB fusion.

Authors:  Shaimaa S Eissa; Michael R Clay; Teresa Santiago; Gang Wu; Lu Wang; Barry L Shulkin; Jennifer Picarsic; Kim E Nichols; Patrick K Campbell
Journal:  Blood Adv       Date:  2020-07-14

7.  Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.

Authors:  Jean Donadieu; Islam Amine Larabi; Mathilde Tardieu; Johannes Visser; Caroline Hutter; Elena Sieni; Nabil Kabbara; Mohamed Barkaoui; Jean Miron; François Chalard; Paul Milne; Julien Haroche; Fleur Cohen; Zofia Hélias-Rodzewicz; Nicolas Simon; Mathilde Jehanne; Alexandra Kolenova; Anne Pagnier; Nathalie Aladjidi; Pascale Schneider; Geneviève Plat; Anne Lutun; Anne Sonntagbauer; Thomas Lehrnbecher; Alina Ferster; Viktoria Efremova; Martina Ahlmann; Laurence Blanc; James Nicholson; Anne Lambilliote; Houda Boudiaf; Andrej Lissat; Karel Svojgr; Fanette Bernard; Sarah Elitzur; Michal Golan; Dmitriy Evseev; Michael Maschan; Ahmed Idbaih; Olga Slater; Milen Minkov; Valerie Taly; Matthew Collin; Jean-Claude Alvarez; Jean-François Emile; Sébastien Héritier
Journal:  J Clin Oncol       Date:  2019-09-12       Impact factor: 44.544

8.  BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.

Authors:  J Picarsic; T Pysher; H Zhou; M Fluchel; T Pettit; M Whitehead; L F Surrey; B Harding; G Goldstein; Y Fellig; M Weintraub; B C Mobley; P M Sharples; M L Sulis; E L Diamond; R Jaffe; K Shekdar; M Santi
Journal:  Acta Neuropathol Commun       Date:  2019-11-04       Impact factor: 7.801

9.  Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH.

Authors:  Amel Sengal; Jessica Velazquez; Meryl Hahne; Thomas M Burke; Harshal Abhyankar; Robert Reyes; Walter Olea; Brooks Scull; Olive S Eckstein; Camille Bigenwald; Catherine M Bollard; Wendong Yu; Miriam Merad; Kenneth L McClain; Carl E Allen; Rikhia Chakraborty
Journal:  Blood       Date:  2021-04-01       Impact factor: 25.476

10.  High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy.

Authors:  Lynn H Lee; Christa Krupski; Jason Clark; Mark Wunderlich; Robert B Lorsbach; Michael S Grimley; Matthew Burwinkel; Adam Nelson; Ashish R Kumar
Journal:  Blood Adv       Date:  2020-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.